Clinical study of AdV-tk radiogene therapy for glioma

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$758,386.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R44CA107745-01
Agency Tracking Number:
CA107745
Solicitation Year:
2004
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2004-2
Small Business Information
ADVANTAGENE, INC.
ADVANTAGENE, INC., 160 PAULSON RD, WABAN, MA, 02468
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ESTUARDO Aguilarcordova
(617) 916-5445
EAGUILAR@ADVANTAGENE.COM
Business Contact:
AMANDA DAVIS
(617) 916-5445
ADAVIS@ADVANTAGENE.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic approaches. Within cancer gene therapy the use of adenovir

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government